I felt the presentation today addressed most of the issues I had in my mind. What did you think of Dr. Algazi's comments on RECIST not being the best measure of efficacy in terms of Melanoma, but that it is the only way they are able to report an FDA accepted measure? Sorry, layman's terms here. Perhaps there is more detail to be derived from the study than what meets the eye.
I thought this was interesting.
Secondly, PD mentioned "positive contact with Merck" (paraphrase) regarding the interim data from the combo trial.
News 
Market Data 
Discover 
AI
